Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Uranus's small moons are dark, red, and water-poor - 2Understanding Successful Compromise Standards to Cultivate Agreeable Connections
- 3Lower-cost space missions like NASA's ESCAPADE are starting to deliver exciting science – but at a price in risk and trade‑offs
- 4Americans generally like wolves − except when we’re reminded of our politics
- 5Tributes pour in for James Ransone, 'The Wire' actor who died at 46
- Ancient fire discovery marks significant milestone in human history
- Radiate brilliantly: The 5 Precious stone Rings to Purchase in 2024
- Trump administration plan to reduce access to some student loans angers nurses, health care groups
- James Webb Space Telescope spies mysterious high-energy radiation in star nursery
- ‘Democratizing space’ is more than just adding new players – it comes with questions around sustainability and sovereignty
- Vote in favor of the handheld vacuum that you love for its strong attractions!
- Idris Elba is the king of the stress-watch
- German finance minister sees advantages of smartphones in schools
- They relied on marijuana to get through the day. But then days felt impossible without it
